Stem cell studies continue to make big news with a mixed bag of trends including for stem cell biotech, and some good stem cell news and others not so much. Mesoblast ($MESO) had its stock suspended for quite so time recently in anticipation of a big announcement. When that news came today it was discouraging in […]
Stem cell biotech bites: Mesoblast, BioTime, MS, FDA Warning, & More Read More »
Here are some headlines & articles worth a look and some thought on stem cell and biomedical science more generally. Gallup finds in a new poll that 60% of Americans surveyed find human embryonic stem celsl research “largely acceptable”. On the other hand human reproductive cloning is highly frowned upon, sandwiched in the “highly unacceptable
Weekend reads: ES cell research polls well, Gordie Howe, MS, IPS cells, and more Read More »
I wrote yesterday about two cases of science media hype on CRISPR and on stem cells for strokes. The latter case on stem cell hype stirred the most discussion and even some harsh words in the comments. As this stem cell stroke story on an encouraging but very small, preliminary study has unfolded across the
Stem cells for stroke hype analysis: 9 very different headlines Read More »
The REGROW Act would drastically weaken FDA regulation of experimental stem cell therapies. I’ve criticized it in numerous posts (see those here) for its radical ideas that would put patients and the stem cell field at risk. I’m not the only one concerned about it as both ARM and ISSCR oppose it too. Now 10 top patient advocacy
Ten patient groups oppose REGROW Act that would gut stem cell oversight Read More »
The fast-moving stem cell field has enjoyed remarkable progress in the past 10 years despite some issues such as instances of stem cell paper retraction. This “modern” stem cell era that includes induced pluripotent stem cells (IPSC) has been striking for progress despite some challenges such as issues with publications. As a maturing field it is important
Higher apparent stem cell paper retraction rates versus cancer papers Read More »
A committee of the International Society for Stem Cell Research (ISSCR) did one heck of a document dump yesterday on stem cell policy, releasing a whole bunch of policy recommendations on stem cells and more. The torrent from ISSCR included a 37-page policy statement itself as well as several papers in top journals including the
ISSCR Releases Flood of Stem Cell Policy Docs Read More »
The FDA has taken another action against a manufacturer of stem cell cosmetics in the form of anti-aging creams with a warning letter sent on April 20, 2016 to Crescent Health Center, Inc. The FDA noted a number of issues in the warning letter that it termed “serious violations”, but the biggest issue was that the agency
FDA warning to stem cell cosmetics maker Read More »
What are the top 10 stem cell websites? Where do you go to find the latest information and opinion on the stem cell and regenerative medicine fields? Today, that information flows almost from minute to minute via websites and from social media. This is a transformational difference from past decades when it would take months.
10 go-to stem cell & regenerative medicine websites of 2016 Read More »
There’s been a lot of buzz the last few days about reviving the dead via stem cells. Is this possible? Who knows, but it would be very long odds. Could it lead to zombies? Not really, but there could be negative outcomes even if it seems to sorta work (more below). Bioquark, Inc. is a
Beyond zombies: reviving dead people with stem cells & lasers? Read More »
The REGROW Act has attracted both support and criticism, including on this blog, for the changes it would mandate in the way the FDA regulates stem cell products. More specifically it would greatly reduce regulation of experimental stem cell products. I believe that would be dangerous to patients and to the stem cell field more
Is REGROW Act anti-embryo research? Pluripotent stem cells excluded Read More »